Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
暂无分享,去创建一个
G. Lenz | S. Meshinchi | M. Dugas | W. Berdel | A. Angenendt | C. Rossig | S. Sandmann | C. Schliemann | M. Arteaga | L. Angenendt | Jan-Henrik Mikesch | M. Wöste
[1] A. Stevens,et al. Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy , 2021, Current Oncology Reports.
[2] J. Tamburini,et al. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells , 2020, Nature Communications.
[3] R. Schiff,et al. The FBXW2–MSX2–SOX2 axis regulates stem cell property and drug resistance of cancer cells , 2019, Proceedings of the National Academy of Sciences.
[4] W. Hiddemann,et al. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia , 2019, Leukemia.
[5] B. Leber,et al. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. , 2018, Cancer cell.
[6] D. Reinhardt,et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012 , 2018, Leukemia.
[7] Hamid Bolouri,et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions , 2017, Nature Medicine.
[8] D. Gerhard,et al. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Carroll,et al. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.
[10] Eva Steliarova-Foucher,et al. International incidence of childhood cancer, 2001–10: a population-based registry study , 2017, The Lancet. Oncology.
[11] D. Pollyea,et al. Therapeutic targeting of acute myeloid leukemia stem cells. , 2017, Blood.
[12] Claude Preudhomme,et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.
[13] Asim Khwaja,et al. Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.
[14] H. Glimm,et al. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia , 2015, Molecular carcinogenesis.
[15] I. Larráyoz,et al. Adrenomedullin and tumour microenvironment , 2014, Journal of Translational Medicine.
[16] S. Brain,et al. Calcitonin gene-related peptide: physiology and pathophysiology. , 2014, Physiological reviews.
[17] S. Raimondi,et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Bertin,et al. Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice , 2013, Clinical Cancer Research.
[19] S. Raimondi,et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia , 2012, Cancer.
[20] Yongzhang Luo,et al. Tumor-Associated Macrophages Promote Angiogenesis and Melanoma Growth via Adrenomedullin in a Paracrine and Autocrine Manner , 2011, Clinical Cancer Research.
[21] Christophe Dussert,et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] H. Salih,et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. , 2009, Cancer research.
[23] Y. Kurihara,et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide , 2008, Proceedings of the National Academy of Sciences.
[24] S. Feig,et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.
[25] L. Kanz,et al. CDCP1 Is a Novel Marker for Hematopoietic Stem Cells , 2003, Annals of the New York Academy of Sciences.
[26] Torsten Hothorn,et al. On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..
[27] N. Brünner,et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. , 2002, The American journal of pathology.